Weining Weng, Tao Meng, Junyi Pu, Linjie Ma, Yi Shen, Zhaohui Wang, Rong Pan, Mingqiao Wang, Caiwei Chen, Lijun Wang, Jianjian Zhang, Biao Zhou, Siyuan Shao, Yu Qian, Shu-Hui Liu, Wenhao Hu, Xun Meng
HER3 is a unique member of the epidermal growth factor receptor family of tyrosine kinases, which is broadly expressed in several cancers, including breast, lung, pancreatic, colorectal, gastric, prostate, and bladder cancers and is often associated with poor patient outcomes and therapeutic resistance. U3-1402/Patritumab-GGFG-DXd is the first successful HER3-targeting ADC molecule with clinical efficacy in non-small cell lung cancer (NSCLC). However, over 60% of patients are non-responsive to U3-1402 due to low target expression levels and responses tend to be in patients with higher target expression levels...
June 11, 2023: Molecular Cancer Therapeutics